Newsletter
Every new paper in this field, in your inbox.
Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery shows potential in preventing peritoneal metastases in high-risk colorectal cancer. Recent randomized controlled trials, including Hipect4, demonstrate improved locoregional disease control with HIPEC, without an increase in complications. Despite negative results in trials like Prophylochip and Colopec,…
Survival analysis of 399 patients with peritoneal metastasis from gastric adenocarcinoma revealed that surgical treatment significantly improves overall survival. Subgroup analysis suggests benefits for patients with certain tumor characteristics and previous chemotherapy. Surgery may be an option to enhance prognosis in specific groups of patients…
Identification of reliable prognostic indicators for different groups of appendiceal mucinous neoplasm patients revealed the Completeness of Cytoreduction (CC) score as a consistent predictor of survival. The Peritoneal Cancer Index (PCI) showed significance in specific subtypes, while the Prior Surgical Score (PSS) predicted outcomes in…
Bromelain enhances cytotoxicity and mucolytic activity in appendiceal cancer tumors, reducing mucin production and increasing drug effectiveness in heated intraperitoneal chemotherapy (HIPEC) treatments. Combined with N-acetylcysteine, bromelain significantly reduces mucin levels and boosts cell death pathways like apoptosis and autophagy. These findings suggest a promising…
Patients with colon cancer at high risk of recurrence benefit from preoperative evaluation, neoadjuvant chemotherapy, and revised intraoperative strategies. Specialized treatments, including hipec intraoperative chemotherapy, improve outcomes for patients with occult peritoneal metastases. Optimized cytoreductive surgical procedures and peritonectomy reduce sites of metastases, enhancing the…
Study demonstrates that combining surgery with HIPEC significantly improves 5- and 10-year overall survival rates and relapse-free survival of LAMN perforation patients without impacting short-term outcomes. Analysis of 91 patients revealed higher survival rates in the HIPEC group compared to non-HIPEC group, highlighting the potential…
A meta-analysis of 16 randomized controlled trials with 1,641 patients assessed the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) for treating and preventing peritoneal carcinomatosis in advanced gastric cancer. Surgery plus HIPEC improved overall survival in both prophylactic (HR 0.56) and therapeutic (HR 0.57) settings, with…
Complete cytoreduction can significantly improve survival and relieve symptoms in patients with small intestinal neuroendocrine tumors metastatic to the liver and peritoneum. Despite initial controversies, achieving complete cytoreduction yielded comparable outcomes in patients with isolated liver metastases and those with liver and peritoneal metastases. Aggressive…
Researchers found that negative pressure wound therapy (NPWT) can significantly reduce surgical site infections (SSIs) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). A study of 178 patients showed lower SSI rates with NPWT (5.6%) compared to standard surgical dressing (11.4%). Multivariate analysis confirmed…
Use of pegsitacianine, a pH-sensitive imaging agent, detected residual disease in 50% of patients undergoing cytoreductive surgery. Pegsitacianine showed high sensitivity, improved surgeon assessment, and had acceptable safety profile. This agent has the potential to enhance detection of residual disease and improve outcomes in peritoneal…
